Penn Pharma Partners With GEA Pharma To Open New Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Penn Pharma Partners With GEA Pharma To Open New Facility



Untitled Document

Penn Pharma, a provider of integrated drug-development, clinical-trial supply, and manufacturing services, has partnered with GEA Pharma Systems to open a new facility for the development and manufacture of oncology drugs. The company invested for £14 million ($19 million), built a high-containment manufacturing plant for the production of multiple APIs in batches of 1–120 kg.

The new 15,000 ft2 site offers a geometrically scalable dispensing, granulation, and blending process from powder to capsules. Highly contained equipment trains were designed to minimize the need for personal protective equipment and reduce the use of isolators to a minimum.

Source: GEA Pharma Systems

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here